China Autoimmune Hemolytic Anemia (AIHA) Therapeutics Market: Segmented by Drug Type (Immunosuppressants, Monoclonal Antibodies and Corticosteroids), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital, Retail and Online Pharmacies)- Size, Share, Growth, Trends, and Forecasts (2019 2028)
- Published Date: 2022-12-28
- Report ID: 139794
- Pages: 200
-
Format:
Report Overview
China Autoimmune Hemolytic Anemia (AIHA) Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Autoimmune Hemolytic Anemia (AIHA) is a rare autoimmune disease characterized by an increased destruction of red blood cells (RBCs) mediated by autoantibodies against autologous RBCs. The China have incidence rate of AIHA in adults is 1 to 3 cases per 100,000 persons. The median age at onset is 52 years.
Market Drivers
China is a growing market for autoimmune hemolytic anemia (AIHA) disease due to improvement in healthcare facilities and approval of new medicines. In addition to this, the emergence of biologics and adoption of novel therapeutics are further pushing the market growth.Other factors that contribute to the growth of the market are increase in Chinas incidence rate (1 to 3 cases per 100,000 persons), government initiatives, genetic and environmental factors.
However, some factors restrain the growth of the autoimmune hemolytic anemia (AIHA) market such as high cost of treatment, potential adverse effects of some medicines.
1. China Autoimmune Hemolytic Anemia (AIHA) Therapeutics Market Overview.
A. Market Size
2. Market Growth Drivers
A. Genetic and Environmental Factors
B. Increase in Incidence Rate
C. Emergence of Biologics
D. Development of Novel Therapeutics
3. Types of Autoimmune Hemolytic Anemia (AIHA) ..
A. Warm Antibody AIHA
B. Cold Antibody AIHA
C. Mixed Type AIHA
D. Drug Induced AIHA
4. Autoimmune Hemolytic Anemia (AIHA) Therapeutics Market Segmentation....
A. By Drug Type
I. Immunosuppressants
II. Monoclonal Antibodies (mAb)
III. Corticosteroids
B. By Route of Administration
I. Oral
II. Parenteral
C. By Distribution Channels
I. Hospital Pharmacies
II. Retail Pharmacies
III. Online Pharmacies
5. Autoimmune Hemolytic Anemia (AIHA) Major Products Market Share
A. Market Analysis, Insights and Forecast By Revenue Type
6. Competitive Landscape.........
A. Major Players
B. Products in Pipeline
7. Key Company Profiles
A. Roche Company Overview, Product & Services, Strategies & Financials
B. Grifols Company Overview, Product & Services, Strategies & Financials
C. Alexion Company Overview, Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
9. Factors Driving Future Growth
A. New Trends and Development of Autoimmune Hemolytic Anemia (AIHA) Therapeutics Market
B. Future Opportunities
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
